Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: Chris Forte who wrote (67516)	9/19/2007 1:06:22 AM
From: Stuki	Respond to of 120415

AXK Chris. Thanks for the heads up. I have AXK too. I think they are a company that is in the right place at the right time. They sure trade thin though; they move up and down on almost no trades. Glad to hear that you are positive on them. I look forward to the day "big brother" walks in the door.

To: Chris Forte who wrote (67516)	9/19/2007 8:49:41 AM
From: Ernest K Brandt	Respond to of 120415

AXK Chris, thanks for the update. I have been here with you since you first mentioned it over a year ago. Ernie

To: Chris Forte who wrote (67516)	9/19/2007 12:12:42 PM
From: Stuki	Respond to of 120415

ONI I think ONI is another interesting medical play. Their antibiotic MU1140 works in a different way from other antibiotics. See their pr of 9/5/07 and their website for more info. Here is the oening of the 9/5 pr, "Oragenics, Inc. (AMEX:ONI - News), a biotechnology development company, announced today laboratory results from a Tier 3 spectrum of activity study, conducted at an independent testing facility, which demonstrated that its lead antibiotic candidate, MU1140(TM), was effective at clinically relevant doses in killing pathogenic bacteria that are resistant to a variety of antibiotics, including all vancomycin-resistant strains of enterococci and Staphylococcus aureus in the Tier 3 Gram-positive bacterial panel. Vancomycin, approved by the FDA in 1958, is still considered the drug of "last resort" and is used for the treatment of serious, life-threatening infections which have not responded to other antibiotics." They also have probitics that they claim will eliminate tooth decay. They have had some false starts and some trouble in formulating tests with the FDA for their tooth decay products. They seem to be on track now. 23 M s/o with 13.5 M float. Any comments greatly appreciated.